Olomoucine and NU2058, which are selective CDK2 inhibitors, were shown to be synergistic with antiandrogens in prostate cancer cells, providing further evidence for this as a possible therapeutic approach [109,110]. Here, CDK2 is linked to prostate carcinoma.